Bayer AG

Featured in: Favicon

wiley.com (+2) Favicon

nature.com Favicon

reuters.com Favicon

bmj.com (+1) Favicon

tandfonline.com Favicon

frontiersin.org Favicon

marketwatch.com Favicon

mdpi.com + 56 more

Articles

Agrochemicals Market Sales to Top USD 382.1 Bn by 2034

Jan 23, 2025 | einpresswire.com | Bayer AG

NEW YORK, NY, UNITED STATES, January 23, 2025 / EINPresswire.com/ -- The global agrochemicals market is a critical component of the agricultural sector, providing essential products that support crop growth and protection. Agrochemicals, which include fertilizers, pesticides, herbicides, and insecticides, play a pivotal role in enhancing crop yield and quality, addressing the pressing need for food production amidst growing global populations and shrinking arable land.
Bayer to acquire camelina assets from Canadian firm to expand its position in feedstock market

Jan 10, 2025 | biobased-diesel.com | Bayer AG

Bayer announced Jan. 9 a deal with Canada-based Smart Earth Camelina Corp. to acquire its camelina germplasm, intellectual property and materials to expand its global-leadership position in biobased-feedstock markets.
Bayer erwirbt Camelina-Assets von Smart Earth Camelina und baut führende Position bei Biokraftstoffen aus

Jan 9, 2025 | pressebox.com | Bayer AG

(PresseBox) () - Vereinbarung enthält das Camelina-Keimplasma und das dazugehörige geistige Eigentum - Mit der Aufnahme von Camelina-Kulturen in das Portfolio baut Bayer seine führende Position bei Biokraftstoffen aus und eröffnet Landwirten zusätzliche Einkommensquellen. Zudem soll so die wachsende Nachfrage nach erneuerbaren Kraftstoffen gedeckt werden - Das übergeordnete Ziel ist die Dekarbonisierung des Transportsektors.
Bayer, Neste to scale winter-canola feedstock for biobased diesel production

Jan 8, 2025 | biobased-diesel.com | Bayer AG

Bayer and Neste, a leading producer of sustainable aviation fuel and renewable diesel, announced Jan. 8 that they have signed a memorandum of understanding (MOU) to jointly scale winter canola as a biomass-based feedstock for renewable products like biofuels. Within the collaboration, the companies are going to develop a winter-canola ecosystem in the Southern Great Plains of the U.S., including product development and additional collaborations to enable Bayer to enter this market.
Bayer beantragt in China die Zulassung für die dritte Indikation von Darolutamid

Jan 7, 2025 | pressebox.com | Bayer AG

(PresseBox) () Antrag basiert auf positiven Ergebnissen der pivotalen Phase-III-Studie ARANOTE, die zeigte, dass Darolutamid plus Androgendeprivationstherapie (ADT) bei Patienten mit metastasiertem hormonsensitivem Prostatakrebs (mHSPC) im Vergleich zu Placebo plus ADT das radiologische Progressions- oder Sterberisiko signifikant um 46% reduzierte Für Darolutamid plus ADT liegen nun positive Daten aus zwei pivotalen Phase-III-Studien bei Patienten mit mHSPC vor, sowohl in Kombination mit als...
soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial | Nephrology Dialysis Transplantation | Oxford Academic

Dec 3, 2024 | academic.oup.com | Francisco Martinez |Francisco Martínez |A Coruna |Bayer AG |Friedrich Alexander

Approximately 2.4% of worldwide mortality is related to chronic kidney disease (CKD) [1]. By 2040, CKD is expected to be the fifth leading cause of life-years lost worldwide [2]. Despite guideline-recommended interventions such as renin–angiotensin system (RAS) inhibition and sodium-glucose co-transporter-2 inhibitors (SGLT2is) [3, 4], patients with CKD remain at risk of disease progression, which may result in kidney replacement therapy [1, 5].
Dual pathway inhibition in patients with atherosclerosis with and without heart failure: insights from the XATOA Registry

Oct 28, 2024 | academic.oup.com | Bayer AG

Patients with atherosclerotic cardiovascular disease (ASCVD) are at a high-risk of experiencing a major adverse cardiovascular event, with 1 in 10 individuals experiencing an event within four years (1). To address this risk of secondary cardiovascular events, there have been renewed efforts to enhance secondary prevention therapies through the application of guideline-directed medical therapy.
Bayer eröffnet Bayer Co.Lab Shanghai im Rahmen weltweiten Ausbaus seines Life-Science-Inkubator-Netzwerks

Sep 26, 2024 | pressebox.com | Bayer AG

(PresseBox) () Das Bayer Co.Lab Shanghai ist Teil des globalen Bayer-Netzwerks von Life-Science-Inkubatoren in wichtigen Innovationszentren wie Cambridge (USA), Kobe (Japan) und Berlin (Deutschland) Der Inkubator in Shanghai bietet Zugang zu Bayer‘s Expertise in der Zell- und Gentherapie sowie in der Onkologie Die Investition unterstreicht das Engagement und die Wachstumsstrategie von Bayer in China Bayer hat heute die Eröffnung seines neuen Life-Science-Inkubators Bayer Co.Lab Shanghai im...
We are MedChem: The Frontiers in Medicinal Chemistry 2024

Sep 23, 2024 | chemistry-europe.onlinelibrary.wiley.com | Matthias Schiedel |Philipp Barbie |Bayer AG |Felix Pape

Conflict of Interests The authors declare no conflict of interest. References 1 1a, , , , , , , , , , , , , , Adv. Sci. 2021, 8, e2100832; 1b, , Chem. Commun. 2017, 53, 2272–2274. 2 2a, , , , , , , Angew. Chem. Int. Ed. 2019, 58, 1674–1678; 2b, , , J. Chem. Inf. Model. 2018, 58, 472–479. 3, , , , , , , Sci. Adv. 2021, 7, eabg3338. 4, , , , , Angew. Chem. Int. Ed. 2021, 60, 19477–19482. 5, , , , , , , , , , , Cell Chem. Biol. 2021, 28, 4–13 e17.
BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases, Bayer AG, Story - PresseBox

Sep 3, 2024 | pressebox.com | Bayer AG

(PresseBox) () OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases / Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in children and adults / BlueRock plans to conduct a Phase 1/2a clinical study in the U.S. Cambridge, MA USA, September 3, 2024 - BlueRock Therapeutics...

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →